PATRIOT Trial: Randomized phase II study of prostate stereotactic body radiotherapy comparing 11 versus 29 days overall treatment time

被引：6
|
作者：
Quon, Harvey Charles
Ong, Aldrich
Cheung, Patrick
Chu, William
Chung, Hans T.
Vesprini, Danny
Chowdhury, Amit
Panjwani, Dilip
Pang, Geordi
Korol, Renee
Davidson, Melanie
Ravi, Ananth
McCurdy, Boyd
Zhang, Liying
Bucher, Oliver
Mamedov, Alexandre
Deabreu, Andrea
Lylyk, Elizabeth
Loblaw, Andrew
机构：
[1] CancerCare Manitoba, Winnipeg, MB, Canada
[2] Sunnybrook Hlth Sci Ctr, Odette Canc Ctr, Toronto, ON M4N 3M5, Canada
[3] BC Canc Agcy, Abbotsford, BC, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 07期
关键词：
D O I：
10.1200/jco.2015.33.7_suppl.6
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6
引用
收藏
页数：1
相关论文
共 50 条
  • [1] PATRIOT Trial: Randomized Phase 2 Study of Prostate Stereotactic Body Radiation Therapy Comparing 11 Versus 29 Days Overall Treatment Time
    Quon, H. C.
    Ong, A.
    Cheung, P.
    Chu, W.
    Chung, H. T.
    Vesprini, D.
    Chowdhury, A.
    Panjwani, D.
    Pang, G.
    Korol, R.
    Davidson, M. T.
    Ravi, A.
    McCurdy, B.
    Zhang, L.
    Bucher, O.
    Mamedov, A.
    Deabreu, A.
    Lylyk, E.
    Loblaw, D. A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2015, 93 (03): : S198 - S198
  • [2] Accelerating prostate stereotactic ablative body radiotherapy: Efficacy and toxicity of a randomized phase II study of 11 versus 29 days overall treatment time (PATRIOT)
    Alayed, Yasir
    Quon, Harvey
    Ong, Aldrich
    Cheung, Patrick
    Chu, William
    Chung, Hans
    Vesprini, Danny
    Chowdhury, Amit
    Panjwani, Dilip
    Pang, Geordi
    Korol, Renee
    Davidson, Melanie
    Ravi, Ananth
    McCurdy, Boyd
    Zhang, Liying
    Mamedov, Alexandre
    Deabreu, Andrea
    Loblaw, Andrew
    RADIOTHERAPY AND ONCOLOGY, 2020, 149 : 8 - 13
  • [3] Accelerating Prostate Stereotactic Ablative Body Radiotherapy (SABR): Efficacy and Toxicity of a Randomized Phase II Study of 11 Versus 29 Days Overall Treatment Time (PATRIOT Study; ClinicalTrials.gov NCT01423474)
    Loblaw, D. A.
    Quon, H. C.
    Ong, A. T.
    Alayed, Y.
    Cheung, P.
    Chu, W.
    Chung, H. T.
    Vesprini, D.
    Chowdhury, A.
    Panjwani, D.
    Pang, G.
    Korol, R.
    Davidson, M. T.
    Ravi, A.
    McCurdy, B.
    Zhang, L.
    Mamedov, A.
    Deabreu, A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : S56 - S56
  • [4] Once-weekly versus every-other-day stereotactic body radiotherapy in patients with prostate cancer (PATRIOT): A phase 2 randomized trial
    Quon, Harvey C.
    Ong, Aldrich
    Cheung, Patrick
    Chu, William
    Chung, Hans T.
    Vesprini, Danny
    Chowdhury, Amit
    Panjwani, Dilip
    Pang, Geordi
    Korol, Renee
    Davidson, Melanie
    Ravi, Ananth
    McCurdy, Boyd
    Zhang, Liying
    Mamedov, Alexandre
    Deabreu, Andrea
    Loblaw, Andrew
    RADIOTHERAPY AND ONCOLOGY, 2018, 127 (02) : 206 - 212
  • [5] Stereotactic body radiotherapy for high-risk prostate cancer (5 treatment days): Toxicity results of a phase II trial.
    Kishan, Amar Upadhyaya
    Fuller, Donald B.
    Steinberg, Michael L.
    Ramirez, Victoria
    Agazaryan, Nzhde
    Ruan, Dan
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [6] Stereotactic Body Radiotherapy for Prostate Cancer: Current Results of a Phase II Trial
    King, Christopher
    IMRT IGRT SBRT- ADVANCES IN THE TREATMENT PLANNING AND DELIVERY OF RADIOTHERAPY, 2011, 43 : 428 - 437
  • [7] Phase II Study of MR-guided Prostate Stereotactic Body Radiotherapy in Seven Days: Toxicity Analysis
    Van Loon, Jens
    Bezuidenhout, Jacques Bodenstein
    Engels, Benedikt
    Soete, Guy
    Everaert, Tim
    Bom, Anne-Sophie
    Vanspeybroeck, Benjamin
    Platteaux, Nele
    Van Laere, Sven
    Gevaert, Thierry
    De Ridder, Mark
    RADIOTHERAPY AND ONCOLOGY, 2024, 194 : S2513 - S2514
  • [8] Stereotactic body radiotherapy treatment for hepatocellular carcinoma: A phase II study
    Durand-Labrunie, J.
    Jarraya, H.
    Boleslawski, E.
    Cattan, S.
    Lacornerie, T.
    Peiffert, D.
    Mirabel, X.
    RADIOTHERAPY AND ONCOLOGY, 2018, 127 : S57 - S57
  • [9] A RANDOMIZED PHASE II TRIAL OF PROSTATE BOOST IRRADIATION WITH STEREOTACTIC BODY RADIOTHERAPY (SBRT) IN HIGH-RISK PROSTATE CANCER. THE PBS TRIAL
    Douvi, Georgia
    Isfahanian, Naghmeh
    Lukka, Himanshu
    IanDayes
    Quan, Kimmen
    Schnarr, Kara Lynne
    Goldberg, Mira
    Wright, Jim
    Hallock, Abhirami
    Ishkanian, Adrian
    Cuthbert, David
    Swaminath, Anand
    Chow, Tom
    Diamond, Kevin
    Cutz, Jean-Claude
    Kavsak, Peter
    Thabane, Lehana
    Tsakiridis, Theodoros
    RADIOTHERAPY AND ONCOLOGY, 2020, 150 : S87 - S88
  • [10] A phase II trial of stereotactic body radiotherapy in 4 fractions for patients with localized prostate cancer
    S. Kawakami
    H. Tsumura
    T. Satoh
    K. Tabata
    A. Sekiguchi
    T. Kainuma
    M. Nakano
    M. Iwamura
    H. Ishiyama
    Radiation Oncology, 17
12345